Inpharma 1548 - 29 Jul 2006

■ A combination of mycophenolate mofetil, low-dose tacrolimus, corticosteroids and interleukin-2 isbest for renal transplant recipients, according toresults from an open-label, multinational studypresented at the World Transplant Congress.1645 renal transplant recipients were randomised toreceive one of four different treatment regimens. At12 months, patients who received interleukin-2induction, corticosteroids, mycophenolate mofetil 1gtwice daily and low-dose tacrolimus had significantlyimproved renal function, compared with patients inthe other groups. The mycophenolate mofetilcombination recipients also showed a reduction inearly transplant rejection of up to 65% and animprovement in organ survival of up to 6%, comparedwith patients in the other groups.Roche. Transplant Patients Keep Their New Kidney Longer and in a HealthierState With CellCept Based Drug Combination. Media Release : 24 Jul 2006.Available from: URL: http://www.roche.com 809065860

1

Inpharma 29 Jul 2006 No. 15481173-8324/10/1548-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved